Q2 EPS Estimate for Cardiol Therapeutics Reduced by Analyst

Cardiol Therapeutics Inc. (NASDAQ:CRDL) – Stock analysts at HC Wainwright decreased their Q2 2026 earnings per share (EPS) estimates for shares of Cardiol Therapeutics in a note issued to investors on Monday, July 27th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings per share of ($0.08) for the quarter, down from their prior forecast of ($0.06). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.26) per share. HC Wainwright also issued estimates for Cardiol Therapeutics’ Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.34) EPS, FY2027 earnings at ($0.43) EPS, FY2028 earnings at $0.41 EPS, FY2029 earnings at $0.87 EPS and FY2030 earnings at $1.78 EPS.

CRDL has been the subject of a number of other reports. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $8.00 price target on shares of Cardiol Therapeutics in a research note on Monday, April 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cardiol Therapeutics in a research note on Wednesday, June 24th. Finally, Wall Street Zen cut Cardiol Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $8.50.

Cardiol Therapeutics Trading Up 3.9%

Cardiol Therapeutics stock opened at $1.20 on Wednesday. The stock has a market cap of $138.30 million, a price-to-earnings ratio of -4.29 and a beta of 0.74. The company’s 50-day moving average price is $1.13 and its two-hundred day moving average price is $1.15. Cardiol Therapeutics has a 52 week low of $0.88 and a 52 week high of $1.71.

Cardiol Therapeutics (NASDAQ:CRDL) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.07) earnings per share for the quarter, hitting the consensus estimate of ($0.07).

Institutional Investors Weigh In On Cardiol Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Tejara Capital Ltd boosted its position in shares of Cardiol Therapeutics by 95.1% during the 4th quarter. Tejara Capital Ltd now owns 5,130,122 shares of the company’s stock valued at $4,893,000 after purchasing an additional 2,500,000 shares in the last quarter. AdvisorShares Investments LLC grew its holdings in shares of Cardiol Therapeutics by 7.3% in the 4th quarter. AdvisorShares Investments LLC now owns 597,977 shares of the company’s stock worth $570,000 after acquiring an additional 40,589 shares during the last quarter. Bank of America Corp DE lifted its position in shares of Cardiol Therapeutics by 1,983.0% in the 3rd quarter. Bank of America Corp DE now owns 551,053 shares of the company’s stock valued at $590,000 after acquiring an additional 524,598 shares in the last quarter. Citadel Advisors LLC grew its position in Cardiol Therapeutics by 1,132.6% during the third quarter. Citadel Advisors LLC now owns 463,462 shares of the company’s stock valued at $496,000 after purchasing an additional 425,862 shares in the last quarter. Finally, Integrity Alliance LLC. acquired a new position in Cardiol Therapeutics in the 4th quarter valued at approximately $416,000. 12.49% of the stock is owned by institutional investors and hedge funds.

About Cardiol Therapeutics

Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.